Life Glow Plus
Super Life Glow
Life Glow Basic
Bone Dense Calcium
Taheebo Life Tea
Germanium
Colloidal Minerals
Methyl Sulfonyl Methane
Transfer Factor
Immune Egg

Vibrant Life Home Web
All VL Products
Family Of Three Chelation Formulas
Oral Chelation Ingredient Comparisons

The Wednesday Letter
Karl Loren Viewpoints
Frequently Asked Questions
Testimonials

Free Radicals
Central Page For 18 Web Sites
Vibrant Life Home Page

Shopping Cart

Separate Search Page
or search below


Navigation Help

Karl Loren Background

Ingredients Technical Write To Karl Loren Table Of Contents

Germanium

carboxyethyl germanium sesquioxide (Ge-132)

Here is a table of scientific studies which include references to the organic substance called carboxyethyl germanium sesquioxide.  This substance was "discovered" and then synthesized by Dr. Kazuhiko Asai, who lived in Japan many years ago.  He wrote THE book, entitled "Miracle Cure Organic Germanium," published in English by Japan Publications, Inc., copyrighted in 1980, LCCC No. 79-91512, ISBN:  0-57040-474-3.

Karl's book was published by Life Extension Educational Service in 1987, Second Edition, (now out of print).

The table below contains the title of the 39 various scientific studies as well as a link to that study on this page.

You'll probably find that this is the only source of scientific information about germanium available on the Internet.

Keep in mind that the ONLY form of germanium for which any anti-cancer claims are made is, technically, germanium carboxyethyl sesquioxide.  I have included studies, below, on "germanium oxide" which is the most common form of germanium.  Germanium oxide is not very toxic -- it takes a dose of about 2 pounds to kill a mouse!  But, the FDA has banned the importation of carboxyethyl germanium sesquioxide into the US, probably instigating "studies" which would show that "germanium" (actually germanium oxide) caused cancer.  These would be spurious references to criticize the true form of germanium which Dr. Asai developed and researched in Japan.

Number

Official Title of the Study

Comments

...1... Mutagenicity, carcinogenicity and
teratogenicity of germanium compounds.
"Germanium is not carcinogenic and even appears to inhibit cancer development and, in the form of the organic germanium compound, spirogermanium, to destroy cancer cells."
...2... Hazard assessment of germanium supplements. Here is one of those fraudulent "studies" actually done by the US Government, claiming toxicity for "germanium."
...3... Effects of germanium oxide and other chemical
compounds on phenylmercury acetate-induced
genotoxicity in cultured human lymphocytes.
Another study showing "dangers."  Note the reference to "germanium oxide" -- not the form recommended by Dr. Asai or sold by Vibrant Life
...4... Multidisciplinary treatment of head and neck
cancer using BCG, OK-432, and GE-132 as
biologic response modifiers.
 
...5... Germanium intoxication with sensory ataxia. Another study on "inorganic germanium" -- which is NOT the one you want.
...6... Applications of a self-collimating BGO
detector system to radiological emergency response.
 
...7... Germanium-induced nephropathy: report of two
cases and review of the literature.
Another study of "germanium oxide."  Germanium oxide can be hidden, with vitamin C, and sold as "germanium sesquioxide" as a fraud.
...8... Inhibitory effects of Ge-132 (carboxyethyl
germanium sesquioxide) derivatives on
enkephalin-degrading enzymes.
 
...9... Phase I trial of spirogermanium given by
infusion in a multiple-dose schedule.
 
..10... Phase II study of spirogermanium in
advanced ovarian malignancy.
 
..11... Phase I clinical trial of spirogermanium.  
..12... Therapeutic effects of organic germanium. "Germanium is present in all living plant and animal matter in micro-trace quantities. Its therapeutic attributes include immuno-enhancement, oxygen enrichment, free radical scavenging, analgesia and heavy metal detoxification. Toxicological studies document Germanium's rapid absorption and elimination from the body, and its safety. Clinical trials and use in private practices for more than a decade have demonstrated Germanium's efficacy in treating a wide range of serious afflictions, including cancer, arthritis and senile osteoporosis. Germanium's anti-viral and immunological properties, including the induction of interferon, macrophages, T-suppressor cells and augmentation of natural killer cell activity, suggest its possible efficacy in treating and/or preventing AIDS. "
..13... Phase II study of N-methylformamide,
spirogermanium, and 4-demethoxydaunorubicin
in the treatment of non-small cell lung cancer
(EST 3583): an Eastern Cooperative Oncology
Group study
 
..14... Tubulointerstitial nephropathy persisting
20 months after discontinuation of chronic
intake of germanium lactate citrate.
 
..15... Abuse of germanium associated with
fatal lactic acidosis.
Another study done with inorganic germanium -- a fraud.
..16... Inhibition by germanium oxide of the mutagenicity
of cadmium chloride in various genotoxicity assays.
 
..17... Effects of proxigermanium on interferon production
and 2',5'-oligoadenylate synthetase activity in the
lung of influenza virus-infected mice and in
virus-infected human peripheral blood mononuclear
cell cultures.
 
..18... Germanium myopathy: clinical and experimental pathological studies. Another misleading study
..19... Renal failure caused by long-term use of a germanium
preparation as an elixir.
Another study of "inorganic" germanium.  These dangerous forms were deliberately spread in Japan, to cause death, so that the FDA could then claim that ALL germanium was deadly, and thus ban import of this cancer-fighting agent.
..20... Identification of synergistic combinations of spirogermanium with 5-fluorouracil or cisplatin using a range of human tumour cell lines in vitro.
Menu Choice #20
..21... A Phase I trial of spirogermanium administered
on a continuous infusion schedule.
 
..22... Nephrotoxicity of germanium compounds: report
of a case and review of the literature
 
..23... Spirogermanium: a new investigational drug of
novel structure and lack of bone marrow toxicity.
 
..24... Phase I study of spirogermanium given daily.  
..25... Nephrotoxicity and neurotoxicity in humans from
organogermanium compounds and germanium dioxide.
 
..26... Identification of 241Am in the axillary lymph nodes
with an intrinsic germanium detector.
 
..27... Performance of an array of large-volume germanium
detectors for whole-body counting.
 
..28... Germanium poisoning: clinical symptoms and renal
damage caused by long-term intake of germanium.
 
..29... Nephrotoxicity in humans by the ultratrace element
germanium.
 
..30... Cytotoxic effects and biological activity of 2-aza-8-germanspiro[4,5]-decane-2-propanamine-
8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium) in vitro.
 
..31... Determination of germanium and some other elements in hair, nail, and toenail from persons exposed and unexposed to germanium.  
..32... Rotating laminar emission camera with GE-detector: an analysis.  
..33... Rotating laminar emission camera with GE-detector: experimental results.  
..34... Rotating laminar emission camera with GE-detector: experimental results.  
..35... A phase II study of spirogermanium in advanced human malignancy.  
..36... Accumulation of germanium in the tissues of a long-term user of germanium preparation died of acute renal failure.  
..37... A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study.  
..38... A phase II study of spirogermanium in patients with metastatic malignant melanoma. An NCI Canada Clinical Trials Group Study. The required dose for treating cancer with the real germanium is about 2,000 mg per day.  This study does not show how much was used -- typically these fraudulent studies use a low dose or a different substance.
..39... Germanium dioxide-induced nephropathy: a new type of renal disease.  

MEDLINE #1
Return To Top Of Menu

Title
Mutagenicity, carcinogenicity and teratogenicity of germanium compounds.
Author
Gerber GB; Léonard A
Address
Teratogenicity and Mutagenicity Unit, Catholic University of Louvain, Brussels, Belgium.
Source
Mutat Res, 1997 Dec, 387:3, 141-6
Abstract
The metalloid germanium has found widespread application in electronics, nuclear sciences and in medicine. General toxicity of germanium is low, except for the tetrahydride germane, and few observations on toxicity of germanium in man exist. Germanium is not carcinogenic and even appears to inhibit cancer development and, in the form of
MeSH Heading
(Major)
Carcinogens|*TO; Germanium|CH/ME/*TO; Mutagens|*TO
MeSH Heading
Animal; Female; Human; Pregnancy
 
The total dose of ingested germanium (as dioxide, carboxyethyl germanium sesquioxide, germanium-lactate-citrate, or unspecified forms) varied from 15 to over 300 g; the exposure duration varied from 2 to 36 months. In laboratory animals, elevated germanium in tissues and impaired kidney and liver function were observed in a life-time drinking water (5 ppm germanium) study. Other toxicities associated with ingested germanium products in human cases were also demonstrated in animal studies with germanium dioxide and sometimes other germanium compounds. Based on the evidence of persistent renal toxicity associated with germanium dioxide, the lack of conclusive findings of differential nephrotoxicity of organic germanium compounds, and the possibility of contamination of the organic germanium products with inorganic germanium, it is clear that germanium products present a potential human health hazard.
Language of Publication
English
Unique Identifier
97380534

MeSH Heading (Major)
Food, Fortified|*; Germanium|*AE/PD/TO; Kidney|*DE; Liver|*DE
MeSH Heading
Administration, Oral; Adolescence; Adult; Anemia|CI; Animal; Antimutagenic Agents|AE/PD/TO; Antineoplastic Agents|AE/PD/TO; Child; Child, Preschool; Female; Human; Kidney Failure|CI; Lethal Dose 50; Male; Middle Age; Muscle Weakness|CI; Neurons|DE; Organometallic Compounds|AE/PD/TO; Risk Assessment

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW OF REPORTED CASES
ISSN
0273-2300
Country of Publication
UNITED STATES

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0027-5107
Country of Publication
NETHERLANDS

Record 2 from database: MEDLINE
Return To Top Of Menu

Title
Hazard assessment of germanium supplements.
Author
Tao SH; Bolger PM
Address
Center for Food Safety and Applied Nutrition, Food and Drug Administration, Washington, DC 20204, USA.
 
Source
Regul Toxicol Pharmacol, 1997 Jun, 25:3, 211-9
Abstract
Germanium-containing dietary supplements became popular in the 1970s in Japan and later in other countries, as elixirs for certain diseases (e.g., cancer and AIDS). Germanium is not an essential element. Its acute toxicity is low. However, at least 31 reported human cases linked prolonged intake of germanium products with renal failure and even death. Signs of kidney dysfunction, kidney tubular degeneration, and germanium accumulation were observed. Other adverse effects were anemia, muscle weakness, and peripheral neuropathy. Recovery of renal function is slow and incomplete even long after germanium intake was stopped.
 

Record 3 from database: MEDLINE
Return To Top Of Menu

Title
Effects of germanium oxide and other chemical compounds on phenylmercury acetate-induced genotoxicity in cultured human lymphocytes.
Author
Lee CH; Lin RH; Liu SH; Lin Shiau SY
Address
Department of Pharmacology, Chung Shang Medical and Dental College, Taichung, Taiwan.
Source
Environ Mol Mutagen, 1998, 31:2, 157-62
Abstract
Phenylmercury acetate (PMA), which not only causes an elevation of sister chromatid exchanges (SCEs) but also induces high frequency of endoreduplication in human lymphocytes, may be genotoxic to humans. The major aim of our study was to investigate the effects of germanium oxide (GeO2), D-penicillamine (D-PA), dimercaprol (BAL), and diltiazem (DTM) on PMA-induced genotoxicity as quantified by SCEs. All concentrations of the four chemical compounds tested alone did not induce genotoxicity in cultured human lymphocytes. However, GeO2 significantly inhibited PMA-induced genotoxicity in a concentration-dependent manner. Similarly, D-PA at concentrations of 3 microM and 10 microM, and BAL at a concentration of 30 microM produced the antigenotoxic effects. In addition, GeO2 (1.5 microM) significantly reversed an increase of endoreduplication frequency caused by PMA. In a cell cycle kinetic study, GeO2 (0.5-5.0 microM) reversed the inhibition of PMA on the proliferating rate index (PRI) of lymphocytes. On the contrary, both D-PA and DTM at concentrations of 30-300 microM markedly potentiated PMA-induced inhibition of PRI. These findings show that GeO2, D-PA and BAL could antagonize PMA-induced genotoxicity, and GeO2 appears to be the most effective.
Language of Publication
English
Unique Identifier
98205834

 


MeSH Heading (Major)
Antidotes|AD/*PD; Antimutagenic Agents|AD/*PD; Fungicides, Industrial|AI/PD/*TO; Germanium|AD/*PD; Lymphocytes|CY/*DE; Phenylmercuric Acetate|AI/PD/*TO
MeSH Heading
Adult; Calcium Channel Blockers|AD/PD; Cells, Cultured; Diltiazem|AD/PD; Dimercaprol|AD/PD; Dose-Response Relationship, Drug; Human; Male; Mitomycin C|PD/TO; Mutagenesis|DE/GE; Nucleic Acid Synthesis Inhibitors|PD/TO; Penicillamine|AD/PD; Sister Chromatid Exchange|DE/GE; Support, Non-U.S. Gov't; Support, U.S. Gov't, Non-P.H.S.

Publication Type
JOURNAL ARTICLE
ISSN
0893-6692
Country of Publication
UNITED STATES

Record 4 from database: MEDLINE
Return To Top Of Menu

Title
Multidisciplinary treatment of head and neck cancer using BCG, OK-432, and GE-132 as biologic response modifiers.
Author
Fukazawa H; Ohashi Y; Sekiyama S; Hoshi H; Abe M; Takahashi M; Sato T
Address
2nd Department of Oral and Maxillofacial Surgery, Niigata University, School of Dentistry, Japan.
Source
Head Neck, 1994 Jan, 16:1, 30-8
Abstract
Since 1979, we have performed multidisciplinary treatment using intensive immunotherapy with biologic response modifiers (BRM) in combination with surgical treatment of oral cancer. Chemotherapy and radiotherapy were also included as part of the therapy. A historic control study was performed. Adjuvant therapy was administered by standardized methods, and the distribution of patients at various stages was similar between groups. The immunotherapy group showed a shorter treatment period, lower rates of recurrence, metastases, and side effects, greater histologic effects at the end of the first treatment, and a higher survival rate than the nonimmunotherapy group. Immunologically, immunotherapy tended to promote positive immune reactions and inhibit negative immune reactions.
Language of Publication
English
Unique Identifier
94171557

 


MeSH Heading (Major)
Antineoplastic Agents|AD/*TU; Biological Response Modifiers|AD/*TU; BCG Vaccine|AD/*TU; Carcinoma|PA/RA/SC/SU/*TH; Germanium|AD/*TU; Head and Neck Neoplasms|PA/RT/SU/*TH; Interferon Inducers|AD/*TU; Organometallic Compounds|AD/*TU; Picibanil|AD/*TU
MeSH Heading
alpha-Macroglobulins|AN; Antineoplastic Agents, Combined|AD/TU; Combined Modality Therapy; Female; Human; Interferons|BI; Male; Middle Age; Neoplasm Proteins|AN; Neoplasm Recurrence, Local; Prognosis; Survival Rate; T-Lymphocytes|PA; Tumor Necrosis Factor|AN

Publication Type
JOURNAL ARTICLE
ISSN
1043-3074
Country of Publication
UNITED STATES

Record 5 from database: MEDLINE
Return To Top Of Menu

Title
Germanium intoxication with sensory ataxia.
Author
Asaka T; Nitta E; Makifuchi T; Shibazaki Y; Kitamura Y; Ohara H; Matsushita K; Takamori M; Takahashi Y; Genda A
Address
Department of Neurology, Kanazawa University School of Medicine, Japan.
Source
J Neurol Sci, 1995 Jun, 130:2, 220-3
Abstract
Sensory ataxia in inorganic germanium intoxication is rare. A 63-year-old housewife had taken inorganic germanium preparations at a dosage of 36 mg a day for about 6 years (total dose about 80 g). She subsequently developed difficulty in writing and gait disturbance with peripheral neuropathy and renal involvement. Germanium, which is not usually detected in the non-germanium user, was accumulated in her hair and nails, permitting a diagnosis of inorganic germanium intoxication. The peripheral neuropathy and renal injury were not reversible after discontinuing the preparation. Pneumonia and sepsis then supervened and the patient died. Autopsy findings showed degeneration and loss of the dorsal root ganglion cells and degeneration of the dorsal column of the spinal cord. Two previously reported cases presented with ataxia. These patients took germanium for long periods and/or large quantities like our case. It was supposed that sensory ataxia was induced by chronic and dose dependent toxicity of inorganic germanium.
Language of Publication
English
Unique Identifier
96172603

 


MeSH Heading (Major)
Ataxia|*CI/PA/PP; Germanium|*PO
MeSH Heading
Aged; Brain|PA; Case Report; Female; Ganglia|PA; Human; Kidney Diseases|CI/PA; Magnetic Resonance Imaging; Motor Neurons|DE; Nerve Degeneration|DE; Neural Conduction|DE; Spinal Cord|PA

Publication Type
JOURNAL ARTICLE
ISSN
0022-510X
Country of Publication
NETHERLANDS

Record 6 from database: MEDLINE
Return To Top Of Menu

Title
Applications of a self-collimating BGO detector system to radiological emergency response.
Author
Pernick A; Orion I; Ilzycer D; Zafrir H
Address
Soreq Nuclear Research Center, Yavne, Israel.
Source
Health Phys, 1997 Jan, 72:1, 136-40
Abstract
The capability of a recently developed BGO detector system featuring a "self-collimating" structure to locate a point source was established by Monte Carlo simulations and by laboratory scale experiments. The detector system's capability to determine the direction of a nuclear plume resulting from a PWR1 or PWR2 type accident in stable atmospheric conditions by airborne monitoring of the 2.4 MeV photons emitted by 88Kr was established by Monte Carlo simulations.
Language of Publication
English
Unique Identifier
97128245

 


MeSH Heading (Major)
Accidents, Radiation|*; Bismuth|*AN; Germanium|*AN; Radiation Monitoring|*MT
MeSH Heading
Cesium Radioisotopes; Human; Krypton Radioisotopes; Monte Carlo Method; Radiation Protection

Publication Type
JOURNAL ARTICLE
ISSN
0017-9078
Country of Publication
UNITED STATES

Record 7 from database: MEDLINE
Return To Top Of Menu

Title
Germanium-induced nephropathy: report of two cases and review of the literature.
Author
Matsusaka T; Fujii M; Nakano T; Terai T; Kurata A; Imaizumi M; Abe H
Address
Division of Cardiovascular and Kidney Disease, Osaka National Hospital, Japan.
Source
Clin Nephrol, 1988 Dec, 30:6, 341-5
Abstract
We report two cases of renal failure following long-term ingestion of germanium dioxide (GeO2) and comment on eight other cases reported in Japan. Ge-induced nephropathy is characterized by insidious onset of renal failure without proteinuria or hematuria after oral intake of Ge-containing compounds for more than several months, and by degeneration of renal tubular cells with minor glomerular abnormality in histology. When patients ceased to ingest Ge compounds, renal function gradually recovered but never returned to the normal range. Serious extrarenal complication can contribute to an unfavorable prognosis.
Language of Publication
English
Unique Identifier
89209410

 


MeSH Heading (Major)
Germanium|*AE/AN/PK; Kidney Failure, Acute|*CI/PA
MeSH Heading
Adult; Case Report; Female; Heart Hypertrophy|ET; Human; Kidney|PA; Male; Middle Age; Myocardium|PA; Time Factors; Tissue Distribution

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW OF REPORTED CASES
ISSN
0301-0430
Country of Publication
GERMANY, WEST
CAS Registry/EC Number
1310-53-8 (germanium oxide); 7440-56-4 (Germanium)

Record 8 from database: MEDLINE
Return To Top Of Menu

Title
Inhibitory effects of Ge-132 (carboxyethyl germanium sesquioxide) derivatives on enkephalin-degrading enzymes.
Author
Komuro T; Kakimoto N; Katayama T; Hazato T
Address
 
Source
Biotechnol Appl Biochem, 1986 Oct, 8:5, 379-86
Abstract
Twenty-eight species of carboxyethyl germanium sesquioxide (Ge-132) derivatives were examined for their inhibitory effects on enkephalin-degrading enzymes that were purified from monkey brain, the longitudinal muscle layer of bovine small intestine, and human cerebrospinal fluid (CSF). A series of the sulfurized Ge-132 derivatives showed strong inhibition of these purified enzymes. The most effective ones were Ge-014 and Ge-107, which showed IC50 values of 60 and 100 micrograms/ml, respectively, for dipeptidylcarboxypeptidase from the longitudinal muscle layer. They also exhibited inhibitory activity against aminopeptidase from human CSF, the IC50 values being 450 and 440 micrograms/ml, respectively. Furthermore, these compounds showed inhibition of dipeptidylaminopeptidase from monkey brain and the longitudinal muscle layer of bovine small intestine. These compounds are expected to have analgesic effects due to their inhibition of the degradation of endogenous opioid peptides.
Language of Publication
English
Unique Identifier
87026253

 


MeSH Heading (Major)
Aminopeptidases|*AI; Carboxypeptidases|*AI; Dipeptidyl Peptidases|*AI; Germanium|*PD; Organometallic Compounds|*PD; Protease Inhibitors|*
MeSH Heading
Analgesics|PD; Animal; Brain|EN; Cattle; Comparative Study; Enkephalins|ME; Guanidines|PD; Haplorhini; Human; Intestine, Small|EN

Publication Type
JOURNAL ARTICLE
ISSN
0885-4513
Country of Publication
UNITED STATES
CAS Registry/EC Number
EC 3.4. (Carboxypeptidases); EC 3.4.- (Peptide Peptidohydrolases); EC 3.4.11. (Aminopeptidases); EC 3.4.14. (Dipeptidyl Peptidases); EC 3.4.15.- (dipeptidyl carboxypeptidase); 0 (Analgesics); 0 (Enkephalins); 0 (Guanidines); 0 (Organometallic Compounds); 0 (Protease Inhibitors); 12758-40-6 (proxigermanium); 7440-56-4 (Germanium); 85713-14-0 (arphamenine A); 88465-81-0 (arphamenine B)

Record 9 from database: MEDLINE
Return To Top Of Menu

Title
Phase I trial of spirogermanium given by infusion in a multiple-dose schedule.
Author
Budman DR; Schulman P; Vinciguerra V; Degnan TJ
Address
 
Source
Cancer Treat Rep, 1982 Jan, 66:1, 173-5
Abstract
In a phase I study of spirogermanium, a new azaspiran-germanium compound, 28 patients were given a multiple-dose schedule. When infused over 1 hour, the maximum tolerated single dose of this agent was greater than 120 mg/m2 but significant chronic neurologic toxicity occurred after 1-2 weeks of treatment. Patients with a poor performance status (PS) were the most likely to manifest toxic reactions. Suggested phage II dose levels for infusion treatment with spirogermanium are 120 mg/m2 for patients with a PS of 0-2 and 80 mg/m2 for patients with a PS of 3.
Language of Publication
English
Unique Identifier
82070170

 


MeSH Heading (Major)
Antineoplastic Agents|*AD/AE; Germanium|*AD/AE; Spiro Compounds|*AD/AE
MeSH Heading
Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Human; Kidney Diseases|CI; Male; Middle Age

Publication Type
JOURNAL ARTICLE
ISSN
0361-5960
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4 (Germanium)

Record 10 from database: MEDLINE
Return To Top Of Menu

Title
Phase II study of spirogermanium in advanced ovarian malignancy.
Author
Tropé C; Mattsson W; Gynning I; Johnsson JE; Sigurdsson K; Orbert B
Address
 
Source
Cancer Treat Rep, 1981 Jan-Feb, 65:1-2, 119-20
Abstract
In the present phase II trial 18 heavily pretreated patients with advanced ovarian malignancy were treated with spirogermanium, 11 im and seven iv. Objective responses (partial remission) were obtained in two (11%) of the 18 patients, with a remission duration of 5 and 23 + months, respectively. An additional four (22%) patients had stable disease. Each of these six patients had a better quality of life. There were few side effects. Myelosuppression, nausea, or other gastrointestinal side effects did not occur. The present investigation shows that spirogermanium is useful as a palliative chemotherapeutic agent in patients with advanced ovarian malignancy.
Language of Publication
English
Unique Identifier
81186146

 


MeSH Heading (Major)
Adenocarcinoma, Mucinous|*DT; Antineoplastic Agents|*TU; Cystadenocarcinoma|*DT; Germanium|*TU; Ovarian Neoplasms|*DT; Spiro Compounds|*TU
MeSH Heading
Drug Evaluation; Female; Human; Neoplasm Recurrence, Local; Remission, Spontaneous

Publication Type
JOURNAL ARTICLE
ISSN
0361-5960
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4 (Germanium)

Record 11 from database: MEDLINE
Return To Top Of Menu

Title
Phase I clinical trial of spirogermanium.
Author
Schein PS; Slavik M; Smythe T; Hoth D; Smith F; Macdonald JS; Woolley PV
Address
 
Source
Cancer Treat Rep, 1980 Oct-Nov, 64:10-11, 1051-6
Abstract
Spirogermanium is a new azaspirane antitumor agent, with the metal germanium substituted for a one-carbon moiety in the ring structure. This drug inhibits DNA and RNA synthesis in HeLa cells, is cytotoxic in vitro, and has curative in vivo antitumor activity against the ascitic Walker 256 carcinosarcoma in rats. No hematologic toxicity was recorded during the preclinical toxicologic evaluation. The principal clinical toxic effects observed in this phase I trial were neurologic, manifested as lethargy, dizziness, and ataxia, while a grand mal seizure was produced after an accidental overdose. There was no evidence of hematologic, renal, or hepatic toxicity. A partial response was achieved in a patient with a well-differentiated lymphocytic lymphoma. We recommend that phase II trials be conducted with a twice or thrice weekly dose of 50-80 mg/m2, administered in a 30-minute iv infusion.
Language of Publication
English
Unique Identifier
81111935

 


MeSH Heading (Major)
Antineoplastic Agents|*TO/TU; Germanium|*TO/TU; Spiro Compounds|*TO/TU
MeSH Heading
Adult; Aged; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hela Cells|DE/ME; Human; Male; Middle Age; Neoplasms|DT; Nervous System Diseases|CI

Publication Type
JOURNAL ARTICLE
ISSN
0361-5960
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4 (Germanium)

Record 12 from database: MEDLINE
Return To Top Of Menu

Title
Therapeutic effects of organic germanium.
Author
Goodman S
Address
International Inst. of Symbiotic Studies, Brighton, Sussex, U.K.
Source
Med Hypotheses, 1988 Jul, 26:3, 207-15
Abstract
Germanium is present in all living plant and animal matter in micro-trace quantities. Its therapeutic attributes include immuno-enhancement, oxygen enrichment, free radical scavenging, analgesia and heavy metal detoxification. Toxicological studies document Germanium's rapid absorption and elimination from the body, and its safety. Clinical trials and use in private practices for more than a decade have demonstrated Germanium's efficacy in treating a wide range of serious afflictions, including cancer, arthritis and senile osteoporosis. Germanium's anti-viral and immunological properties, including the induction of interferon, macrophages, T-suppressor cells and augmentation of natural killer cell activity, suggest its possible efficacy in treating and/or preventing AIDS.
Language of Publication
English
Unique Identifier
88301938

 


MeSH Heading (Major)
Germanium|TO/*TU
MeSH Heading
Acquired Immunodeficiency Syndrome|DT; Animal; Antineoplastic Agents|TU; Arthritis|DT; Clinical Trials; Female; Human; Leukemia, Experimental|DT; Lung Neoplasms|DT; Lymphoproliferative Disorders|DT; Malaria|DT; Organometallic Compounds|TU; Osteoporosis|DT; Ovarian Neoplasms|DT; Spiro Compounds|TU

Publication Type
CLINICAL TRIAL; JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0306-9877
Country of Publication
ENGLAND
CAS Registry/EC Number
0 (Antineoplastic Agents); 0 (Organometallic Compounds); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4 (Germanium)

Record 13 from database: MEDLINE
Return To Top Of Menu

Title
Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study.
Author
Ettinger DS; Finkelstein DM; Donehower RC; Chang AY; Green M; Blum R; Hahn RG; Ruckdeschel JC
Address
Johns Hopkins Oncology Center, Baltimore, Maryland ff205.
Source
Med Pediatr Oncol, 1989, 17:3, 197-201
Abstract
One hundred forty-four patients with non-small cell lung cancer, the majority (72%) of whom had received previous chemotherapy, were evaluable in this randomized phase II study of N-methylformamide (N-MF), spirogermanium, and 4-demethoxydaunorubicin. There were two partial responses, one each with spirogermanium and 4-demethoxydaunorubicin. There were eight life-threatening complications (mostly hematologic) and two lethal complications (N-MF, hematologic; 4-demethoxydaunorubicin, gastrointestinal). The overall survival ranged from 9 days to 533 days with a median of 17.6 weeks. The following factors were associated with poor survival: Poor initial performance status, prior weight loss, presence of liver or subcutaneous metastases.
Language of Publication
English
Unique Identifier
89313530

 


MeSH Heading (Major)
Antineoplastic Agents|AE/*TU; Carcinoma, Non-Small-Cell Lung|*DT; Formamides|AE/*TU; Germanium|AE/*TU; Idarubicin|*TU; Lung Neoplasms|*DT; Organometallic Compounds|AE/*TU; Spiro Compounds|AE/*TU
MeSH Heading
Aged; Drug Evaluation; Female; Human; Male; Middle Age; Prognosis; Random Allocation; Remission Induction; Support, U.S. Gov't, P.H.S.

Publication Type
CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
ISSN
0098-1532
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Antineoplastic Agents); 0 (Formamides); 0 (Organometallic Compounds); 0 (Spiro Compounds); 123-39-7 (methylformamide); 41992-23-8 (spirogermanium); 58957-92-9 (Idarubicin); 7440-56-4 (Germanium)

Record 14 from database: MEDLINE
Return To Top Of Menu

Title
Tubulointerstitial nephropathy persisting 20 months after discontinuation of chronic intake of germanium lactate citrate.
Author
Hess B; Raisin J; Zimmermann A; Horber F; Bajo S; Wyttenbach A; Jaeger P
Address
Policlinic of Medicine, University Hospital, Berne, Switzerland.
Source
Am J Kidney Dis, 1993 May, 21:5, 548-52
Abstract
Two young human immunodeficiency virus (HIV)-infected patients, a 25-year-old woman and a 26-year-old man, consumed large amounts of germanium lactate citrate 18% as an "immunostimulant" for 9 months. The woman, who had stage II HIV infection, developed severe renal dysfunction (creatinine clearance, 7 mL/min/1.73 m2) and slight proteinuria (0.28 g/d) after ingesting 260 g germanium lactate citrate 18%. Hepatomegaly with liver dysfunction (SGOT, 102 U/L; gamma-glutamyl transferase (GT), 159 U/L) and lactic acidosis (plasma lactate, 7.3 mmol/L) developed simultaneously. Renal biopsy revealed tubulointerstitial nephropathy with vacuolar cell degeneration and periodic acid-Schiff-positive intracellular deposits mainly in distal tubules. Liver biopsy disclosed severe hepatic steatosis; liver function tests returned to normal within 5 weeks. Since renal failure persisted for 2 years after ingestion of germanium (creatinine clearance, 14 mL/min/1.73 m2; proteinuria, 0.84 g/d), a second renal biopsy was performed, which showed marked but focal distal tubular atrophy and slight interstitial fibrosis. The male patient, who had stage III HIV infection, had ingested the same compound; he presented with a creatinine clearance of 43 mL/min/m2 and proteinuria of 0.36 g/d. Renal biopsy disclosed tubulointerstitial changes similar to those found in the female patient. After 9 months off germanium, creatinine clearance remained unchanged. Neutron activation analysis of all biopsy specimens in both cases documented germanium concentrations 10 to 70 times normal in renal tissue and 140 times normal in liver tissue.
Language of Publication
English
Unique Identifier
93256055

 


MeSH Heading (Major)
Germanium|AD/*AE; HIV Infections|*DT; Nephritis, Interstitial|*CI/PA
MeSH Heading
Adult; Case Report; Chronic Disease; Female; Human; Kidney Tubules|PA/UL; Male; Microscopy, Electron; Time Factors

Publication Type
JOURNAL ARTICLE
ISSN
0272-6386
Country of Publication
UNITED STATES
CAS Registry/EC Number
7440-56-4 (Germanium)

Record 15 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Abuse of germanium associated with fatal lactic acidosis.
Author
Krapf R; Schaffner T; Iten PX
Address
Department of Medicine, Hospital of St. Gall, Switzerland.
Source
Nephron, 1992, 62:3, 351-6
Abstract
Germanium compounds are marketed as nonprescription drugs in Europe and are recommended by the suppliers for AIDS and metastatic cancer disease. We observed a patient with nonmetastatic breast cancer who died because of severe lactic acidosis (plasma lactate concentration = 27 mmol/l) after ingestion of 25 g of elemental germanium over a 2-months period. Renal failure and hepatotoxicity had newly developed during germanium intake. Postmortem examination revealed severe hydropic vacuolation of tubule cells and the presence of inclusion bodies predominantly in straight proximal tubule cells with normal appearance of renal interstitium and glomeruli. The liver showed panlobular steatosis. Urine, blood and tissue (kidney, liver, muscle, pancreas) levels of germanium were high. Lactic acidosis may have been caused by the combined, germanium-induced renal and hepatic failure (underutilization), but it remains to be seen whether germanium can affect lactate production and/or metabolism directly.
Language of Publication
English
Unique Identifier
93063655

 


MeSH Heading (Major)
Acidosis|*CI; Germanium|*PO; Lactates|*BL
MeSH Heading
Adult; Case Report; Female; Human; Kidney Failure, Acute|CI; Liver Diseases|CI; Pancreatitis|CO

Publication Type
JOURNAL ARTICLE
ISSN
0028-2766
Country of Publication
SWITZERLAND
CAS Registry/EC Number
0 (Lactates); 50-21-5 (Lactic Acid); 7440-56-4 (Germanium)

Record 16 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Inhibition by germanium oxide of the mutagenicity of cadmium chloride in various genotoxicity assays.
Author
Han C; Wu G; Yin Y; Shen M
Address
Department of Hygiene, Yanbian Medical College, Yanji City, Jilin Province, China.
Source
Food Chem Toxicol, 1992 Jun, 30:6, 521-4
Abstract
The effects of germanium oxide on the genotoxicity of cadmium chloride were investigated. The incorporation of [3H]thymidine into testicular DNA was inhibited in mice injected ip with 1.35, 1.80 or 2.70 mg cadmium chloride/kg body weight. Germanium oxide (0.05 or 0.1 mg/kg body weight, sc) alone did not affect [3H]thymidine incorporation into testicular DNA but 0.05 mg germanium oxide/kg antagonized the inhibitory effect of 1.35 mg cadmium chloride/kg. However, combinations of the other doses of the two compounds did not show statistically significant antagonistic effects. Cadmium chloride significantly increased the frequencies of micronucleus formation in polychromatic erythrocytes, and of chromosome aberrations in the bone marrow of mice treated with 0.7, 1.4 or 2.7 mg/kg body weight, in a dose-related manner. These effects were inhibited by germanium oxide at doses of 0.1 or 0.5 mg/kg body weight, although germanium oxide alone did not affect micronucleus formation or the chromosome aberration rate. Cadmium chloride produced a dose-related increase in the frequency of sister chromatid exchanges in cultured human lymphocytes at concentrations of 5, 10 or 50 mumol. This effect was also inhibited by germanium oxide (0.05 or 0.1 mumol), although germanium oxide alone had no effect. There was a dose-related increase in the frequency of sperms with abnormal head morphologies from mice treated with 0.6, 1.1 or 2.2 mg cadmium chloride/kg body weight and this too was antagonized by the injection of germanium oxide (0.1 or 0.5 mg/kg body weight). Germanium oxide alone did not affect the frequency of sperm-head abnormalities.
Language of Publication
English
Unique Identifier
92363327

 


MeSH Heading (Major)
Antimutagenic Agents|*PD; Cadmium|*AI/TO; Chlorides|*AI/TO; Chromosomes|*DE; DNA|BI/*DE; Germanium|*PD
MeSH Heading
Animal; Bone Marrow|CY/DE; Chromosome Aberrations; Dose-Response Relationship, Drug; Human; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Micronucleus Tests; Sister Chromatid Exchange|DE; Sperm Head|DE

Publication Type
JOURNAL ARTICLE
ISSN
0278-6915
Country of Publication
ENGLAND
CAS Registry/EC Number
0 (Antimutagenic Agents); 0 (Chlorides); 10108-64-2 (Cadmium Chloride); 1310-53-8 (germanium oxide); 7440-43-9 (Cadmium); 7440-56-4 (Germanium); 9007-49-2 (DNA)

Record 17 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Effects of proxigermanium on interferon production and 2',5'-oligoadenylate synthetase activity in the lung of influenza virus-infected mice and in virus-infected human peripheral blood mononuclear cell cultures.
Author
Ishiwata Y; Yokochi S; Suzuki E; Michishita H; Tashita A; Asano K; Mitani T; Kurono M
Address
Mie Laboratory, Sanwa Kagaku Kenkyusho Co. Ltd., Japan.
Source
Arzneimittelforschung, 1990 Aug, 40:8, 896-9
Abstract
Proxigermanium (SK-818) is a synthesized organic germanium compound having various biological activities. The effects of proxigermanium on interferon (IFN) production in mice infected with influenza virus and virus-infected human peripheral blood mononuclear cells (hPBMC) were investigated. Proxigermanium alone did not induce IFN production in normal mice or in hPBMC without viral infection. On the other hand, proxigermanium enhanced alpha/beta IFN production in viral-infected mice and hPBMC. Since proxigermanium is known to have antiviral activity in vivo but not in vitro, it is likely that the IFN production augumenting activity of proxigermanium is involved in its antiviral activities.
Language of Publication
English
Unique Identifier
91054674

 


MeSH Heading (Major)
Adjuvants, Immunologic|*PD; Germanium|*PD; Influenza|*ME; Interferons|*BI; Lung|*EN; Neutrophils|DE/*EN; Organometallic Compounds|*PD; 2',5'-Oligoadenylate Synthetase|*ME
MeSH Heading
Animal; Cells, Cultured; Human; Indicators and Reagents; Influenza A Virus, Human; Mice; Mice, Inbred BALB C

Publication Type
JOURNAL ARTICLE
ISSN
0004-4172
Country of Publication
GERMANY
CAS Registry/EC Number
EC 2.7.7.- (2',5'-Oligoadenylate Synthetase); 0 (Adjuvants, Immunologic); 0 (Indicators and Reagents); 0 (Organometallic Compounds); 12758-40-6 (proxigermanium); 7440-56-4 (Germanium); 9008-11-1 (Interferons)

Record 18 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Germanium myopathy: clinical and experimental pathological studies.
Author
Higuchi I; Izumo S; Kuriyama M; Suehara M; Nakagawa M; Fukunaga H; Osame M; Ohtsubo S; Miyata K
Address
Third Department of Internal Medicine, Faculty of Medicine, Kagoshima University, Japan.
Source
Acta Neuropathol (Berl), 1989, 79:3, 300-4
Abstract
Pathological examinations were carried out on the skeletal muscle of a patient with germanium intoxication. The prominent histochemical finding was vacuolar myopathy with lipid excess, increased acid phosphatase activity and decreased cytochrome c oxidase activity. Ultrastructural lesions revealed a mitochondrial abnormality, autophagic vacuoles and accumulation of high electron-dense materials in deformed mitochondria and at the periphery of lipid droplets. Furthermore, the toxic effect of germanium on skeletal muscle was confirmed by the experimentally induced germanium myopathy, which showed autophagic degeneration, decreased cytochrome c oxidase activity and a mitochondrial abnormality with high electron-dense materials.
Language of Publication
English
Unique Identifier
90118781

 


MeSH Heading (Major)
Germanium|*AE; Muscular Diseases|*CI/PA
MeSH Heading
Case Report; Child, Preschool; Human; Male; Muscles|UL

Publication Type
JOURNAL ARTICLE
ISSN
0001-6322
Country of Publication
GERMANY, WEST
CAS Registry/EC Number
7440-56-4 (Germanium)

Record 19 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Renal failure caused by long-term use of a germanium preparation as an elixir.
Author
Okada K; Okagawa K; Kawakami K; Kuroda Y; Morizumi K; Sato H; Morita H; Shimomura S; Saito S
Address
Department of Pediatrics, School of Medicine, University of Tokushima, Japan.
Source
Clin Nephrol, 1989 Apr, 31:4, 219-24
Abstract
Two Japanese women and one Japanese man, who had been taking the same germanium preparation, mainly containing inorganic germanium, as an elixir for health almost every day at 90 mg of germanium per day for 6 to 20 months, suffered from chronic renal failure. Histological examination of the kidney in one patient showed marked interstitial changes with vacuolar degeneration of the renal tubules. High germanium concentrations were found in hair and nails of the three patients, but no germanium was detected in hair or nails of normal persons. These results suggest that long-term use of a germanium preparation at high dosage can cause serious renal tubular damage and renal failure due to germanium toxicity.
Language of Publication
English
Unique Identifier
89230846

 


MeSH Heading (Major)
Germanium|AN/*PO/TU; Kidney Failure, Chronic|*CI/PA
MeSH Heading
Adult; Case Report; Female; Hepatitis B|TH; Human; Kidney|PA; Male

Publication Type
JOURNAL ARTICLE
ISSN
0301-0430
Country of Publication
GERMANY, WEST
CAS Registry/EC Number
7440-56-4 (Germanium)

Record 20 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Identification of synergistic combinations of spirogermanium with 5-fluorouracil or cisplatin using a range of human tumour cell lines in vitro.
Author
Hill BT; Bellamy AS; Metcalfe S; Hepburn PJ; Masters JR; Whelan RD
Address
 
Source
Invest New Drugs, 1984, 2:1, 29-33
Abstract
A series of continuous human tumour cell lines, derived from various tumour types, were used to establish whether the combination of spirogermanium (SP) with other 'standard' antitumour drugs proved superior to these as single agents in reducing cell survival in vitro. A non-cytotoxic concentration of SP was selected and when combined with a range of concentrations of cisplatin or 5-fluorouracil (5-FU), definite synergistic cell kill was noted in all lines tested. In contrast, the combination of SP with various other antitumor drugs, including adriamycin, methotrexate and the vinca alkaloids and with X-irradiation did not enhance cytotoxicity. These pre-clinical in vitro studies suggest that benefit may accrue from combining SP with either 5-FU or cisplatin and provide a basis for their clinical evaluation in colo-rectal tumours or transitional cell cancer of the bladder, respectively.
Language of Publication
English
Unique Identifier
84288357

 


MeSH Heading (Major)
Antineoplastic Agents|*AD/PD; Antineoplastic Agents, Combined|*; Cisplatin|*AD/PD; Colony-Forming Units Assay|*; Fluorouracil|*AD/PD; Germanium|*AD/PD; Spiro Compounds|*AD/PD; Tumor Stem Cell Assay|*
MeSH Heading
Cell Line; Cell Survival|DE; Doxorubicin|PD; Drug Synergism; Human; Methotrexate|PD

Publication Type
JOURNAL ARTICLE
ISSN
0167-6997
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Antineoplastic Agents); 0 (Antineoplastic Agents, Combined); 0 (Spiro Compounds); 15663-27-1 (Cisplatin); 23214-92-8 (Doxorubicin); 41992-23-8 (spirogermanium); 51-21-8 (Fluorouracil); 59-05-2 (Methotrexate); 7440-56-4 (Germanium)

Record 21 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
A Phase I trial of spirogermanium administered on a continuous infusion schedule.
Author
Woolley PV; Ahlgren JD; Byrne PJ; Priego VM; Schein PS
Address
 
Source
Invest New Drugs, 1984, 2:3, 305-9
Abstract
We have evaluated the toxicity of the antitumor agent spirogermanium on a schedule of continuous intravenous administration for periods up to five days. The doses tested were between 100 mg/m2/day and 500 mg/m2/day. Peripheral vein phlebitis occurred at all dose levels and was not relieved by addition of hydrocortisone or heparin to the infusion. No phlebitis occurred when the drug was administered through a central vein. The dose limiting toxicity of spirogermanium was neurologic, notably tremors and mental confusion. These problems became progressively more severe at doses above 250 mg/m2/day. There was no discernible bone marrow, renal or hepatic toxicity. One patient developed reversible interstitial pneumonitis. The recommended Phase II dose of spirogermanium is 200 mg/m2/day for five days, with the possibility of escalation in selected patients. Because spirogermanium is more toxic to tumor cells with prolonged exposure than with intermittent exposure, this schedule could be considered for Phase II trials, particularly in diseases thought to be especially sensitive such as ovarian and prostatic carcinoma or lymphomas.
Language of Publication
English
Unique Identifier
85078935

 


MeSH Heading (Major)
Antineoplastic Agents|AD/*AE/BL; Germanium|AD/*AE/BL; Spiro Compounds|AD/*AE/BL
MeSH Heading
Adult; Aged; Drug Evaluation; Female; Human; Infusions, Parenteral; Male; Middle Age; Neoplasms|DT; Nervous System|DE; Phlebitis|CI; Support, Non-U.S. Gov't

Publication Type
JOURNAL ARTICLE
ISSN
0167-6997
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4 (Germanium)

Record 22 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Nephrotoxicity of germanium compounds: report of a case and review of the literature.
Author
Takeuchi A; Yoshizawa N; Oshima S; Kubota T; Oshikawa Y; Akashi Y; Oda T; Niwa H; Imazeki N; Seno A; et al
Address
Department of Pathology, National Defense Medical College, Saitama, Japan.
Source
Nephron, 1992, 60:4, 436-42
Abstract
A 55-year-old woman was admitted to our hospital, complaining of general malaise, muscular weakness, anorexia and weight loss. She had a history of ingesting of a certain germanium (Ge) compound over the preceding 19 months, with a total dose of 47 g as Ge element. She was found to have renal failure (blood urea nitrogen, 44 mg/dl; serum creatinine, 2.6 mg/dl) without abnormal findings in urinalysis, and muscular and nervous damage. Initially, polymyositis was diagnosed and prednisolone administered. However, no improvement was seen, and neuromuscular symptoms and signs steadily worsened, ending in death. Microscopic study of the kidney showed that lipofuscin granules increased in the cells of the thick ascending limb of Henle's loop to the distal convoluted tubule accompanying mild tubular atrophy and that some of the tubules of these segments had vacuolar degeneration or desquamation. No apparent glomerular and vascular changes were observed. High Ge content was found in serum, urine and various tissues, e.g., spleen, liver, kidney, adrenal gland and myocardium, while in controls Ge could not be detected in sera, urine or tissues. We also review case reports about Ge toxicity, and discuss the pathogenesis of renal failure induced by Ge compounds.
Language of Publication
English
Unique Identifier
92261746

 


MeSH Heading (Major)
Germanium|AD/*TO; Kidney|*DE/PA
MeSH Heading
Case Report; Female; Human; Kidney Failure, Acute|CI/PA; Middle Age; Muscles|DE; Nervous System|DE

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW OF REPORTED CASES
ISSN
0028-2766
Country of Publication
SWITZERLAND
CAS Registry/EC Number
7440-56-4 (Germanium)

Record 23 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity.
Author
Slavik M; Blanc O; Davis J
Address
 
Source
Invest New Drugs, 1983, 1:3, 225-34
Abstract
Spirogermanium (NSC 192965) is a new metallic investigational anticancer drug of novel heterocyclic structure. Although its mode of action has not been fully elucidated, it appears that spirogermanium is not a phase or cell cycle specific drug and inhibits DNA, RNA and protein synthesis, the protein synthesis being the most susceptible to this agent. Spirogermanium has shown cytotoxic activity in vitro against several human tumor cell lines at concentrations (1 micrograms/ml) that were also found toxic to the cultured rat neurons. Although spirogermanium has no effect on normal bone marrow colony forming cells in mice, dogs, or man, it has revealed cytotoxic activity in vitro against human myeloid leukemia cell line K 562 at clinically achievable concentrations. These in vitro findings, indicating selective cytotoxic activity against leukemic cells suggest this drug as a candidate for clinical studies in acute and chronic leukemias. Spirogermanium has revealed activity in vivo against intraperitoneally implanted Walker 256 sarcoma, 13762 mammary adenocarcinoma, and 11095 prostatic carcinoma in rats, but no antitumor activity in vivo was found in the murine tumors used in the past by the NCI screen (L 1210 and P 388 leukemia, B 16 melanoma, Lewis lung carcinoma). Spirogermanium is remarkable for its lack of bone marrow toxicity confirmed in preclinical toxicology and clinical studies; moderate, predictable, and reversible CNS toxicity is dose-limiting. Activity in malignant lymphoma, ovarian cancer, breast cancer, large bowel cancer, and prostatic cancer was reported in the clinical studies. The drug is currently under clinical investigation against the wide spectrum of solid tumors and malignant lymphomas. The dose of 80-120 mg/m2, given by 60' infusion three times a week, is currently used and tolerated in Phase II clinical studies. The recently introduced five days continuous infusion schedule has been also under clinical investigation and the doses of 250-300 mg/m2/day are recommended for Phase II studies. Of interest are results reported in this paper of spirogermanium in vitro preferential activity against the resistant strains of Plasmodium falciparum at clinically achievable concentrations suggesting this drug as a possible new antimalarial agent of novel structure.
Language of Publication
English
Unique Identifier
84288335

 


MeSH Heading (Major)
Antineoplastic Agents|AE/*PD/TU; Bone Marrow|*DE; Germanium|*PD/TO/TU; Spiro Compounds|*PD/TO/TU
MeSH Heading
Animal; Chemistry; Dogs; Drug Evaluation; Human; Mice; Neoplasms|DT; Neoplasms, Experimental|DT; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

Publication Type
JOURNAL ARTICLE
ISSN
0167-6997
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4 (Germanium)

Record 24 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Phase I study of spirogermanium given daily.
Author
Legha SS; Ajani JA; Bodey GP
Address
 
Source
J Clin Oncol, 1983 May, 1:5, 331-6
Abstract
Spirogermanium, an azaspirane compound, has recently had limited clinical trials using a schedule of intravenous injection one to three times every week. The observation of clinical antitumor activity and lack of myelosuppression prompted us to investigate further the clinical effects of spirogermanium administered on various schedules. A total of 52 patients with advanced metastatic tumors refractory to standard therapy were treated with spirogermanium. Three different schedules of drug administration were evaluated. Initially, a short daily IV infusion for 5 days every week was evaluated, starting with a dose of 30 mg/m2/day. A total of 22 patients received 69 courses with a dose range of 30-120 mg/m2/day for 5 days every week. The maximum tolerated dose was 100 mg/m2/day IV over 1 hr and 120 mg/m2 over 2-3 hr. In the second phase of the study, 12 patients received 41 courses of spirogermanium as a 24-hr continuous infusion for 5 days/wk at a dose of 150-375 mg/m2/day. The maximum tolerated dose was 200 mg/m2/day for 5 days. In the third phase of the study, 18 patients received spirogermanium as a continuous infusion daily for a median of 30 days (range 6-77 days) in a dose range of 100-200 mg/m2/day. The maximum tolerated dose was 150 mg/m2/day. Of the 44 assessable patients, 3 demonstrated a partial response and 3 had minor tumor regression; all responses occurred in lymphoma patients. The dose-limiting toxicity of spirogermanium was neurologic; other side effects consisted of mild anorexia, nausea and vomiting, and possible lung toxicity. There was no clear evidence of cumulative toxicity despite daily administration of spirogermanium. Our data suggest that spirogermanium can be administered daily by several different schedules, and the optimum dose depends on the infusion time and the duration of therapy. The delivery of drug by continuous infusion permitted administration of twofold higher dose levels compared to the standard IV schedules used in previous studies.
Language of Publication
English
Unique Identifier
84137813

 


MeSH Heading (Major)
Colonic Neoplasms|*DT; Germanium|*AD/AE; Lymphoma|*DT; Ovarian Neoplasms|*DT; Spiro Compounds|*AD/AE
MeSH Heading
Adult; Aged; Comparative Study; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Human; Infusions, Parenteral; Male; Middle Age; Nausea|CI; Nervous System Diseases|CI

Publication Type
JOURNAL ARTICLE
ISSN
0732-183X
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4 (Germanium)

Record 25 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Nephrotoxicity and neurotoxicity in humans from organogermanium compounds and germanium dioxide.
Author
Schauss AG
Address
Life Sciences Division, American Institute for Biosocial Research, Inc., Tacoma, WA 98401.
Source
Biol Trace Elem Res, 1991 Jun, 29:3, 267-80
Abstract
There is no known biological requirement for germanium (Ge), germanates, or any organogermanium compound. Ge deficiency has not been demonstrated in any animal. The estimated average dietary intake of Ge in humans is 1.5 mg/d. Ge is widely distributed in edible foods, all of which, with few exceptions, contain less than 5 ppm Ge, since higher levels are toxic to most plants. Ingestion of Ge compounds has been shown to produce toxic effects in experimental animals. In recent years inorganic germanium salts and novel organogermanium compounds, such as carboxyethyl germanium sesquioxide (Ge-132) and lactate-citrate-germanate (Ge lactate citrate) have been sold as "nutritional supplements" in some countries for their purported immunomodulatory effects or as health-producing elixirs, resulting in intakes of Ge significantly exceeding the estimated average dietary intake. Since 1982, there have been 18 reported cases of acute renal dysfunction or failure, including two deaths, linked to oral intake of Ge elixirs containing germanium dioxide (GeO2) or Ge-132. In these cases, biopsies show vacuolar degeneration in renal tubular epithelial cells, without proteinuria or hematuria, in the absence of glomerular changes. Serum creatinine levels have been well above 400 mumol/L in such patients. In 17 of 18 cases, accumulated elemental Ge intakes reportedly ranged between 16 to 328 g over a 4-36 mo period, or between 100 to 2000 times the average estimated dietary intake for human. In surviving patients, renal function improved after discontinuation of Ge supplementation. However, in no case was recovery complete. One organogermanium compound, an azaspiran organogermanium compound, 2-aza-8-germanspiro[4,5] decane-2-propamine-8,8-diethyl-N,N-dimethyl dichloride (spirogermanium), has been found to cause both neurotoxicity and pulmonary toxicity in phase I and II studies examining its chemotherapeutic potential as an antitumor drug in the treatment of various malignancies. In cancer patients given the drug spirogermanium, 40% experienced marked, yet transient neurotoxicity. Two patients suffered from pulmonary toxicity. Results of phases I and II human cancer trials for spirogermanium have not been favorable, with the exception of moderate benefits for three types of malignancies. It is recommended that patients exposed to long-term (greater than 3 mo) Ge supplementation at levels well above the estimated daily intake be medically supervised and monitored for potential renal-, pulmonary- or neurotoxicity. Further study regarding the mechanism of Ge-induced nephrotoxicity in human is warranted.
Language of Publication
English
Unique Identifier
92304696

 


MeSH Heading (Major)
Germanium|*TO; Kidney|DE/*PA; Nervous System|DE/*PA; Organometallic Compounds|*TO
MeSH Heading
Animal; Creatinine|BL; Human; Kidney Function Tests; Kidney Tubules|DE/PA; Lethal Dose 50; Mice

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0163-4984
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Organometallic Compounds); 1310-53-8 (germanium oxide); 60-27-5 (Creatinine); 7440-56-4 (Germanium)

Record 26 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Identification of 241Am in the axillary lymph nodes with an intrinsic germanium detector.
Author
Graham SG; Kirkham SJ
Address
 
Source
Health Phys, 1983, 44 Suppl 1:, 343-52
Abstract
A routine measurement with two 200 mm-diameter phoswich detectors, placed one each side of the sternum, yielded an apparent lung content of 17 nCi 241Am for a subject. subject. Inspection of the data revealed that there were many more counts from the left side than from the right and that there was a greater number of Np L X rays observed, relative to the L gamma ray, than would be expected for a uniform lung distribution of 241Am. These observations suggested a shallow localised deposit in the left side of the chest. The subject's working history could not rule out an inhalation exposure, but he was known to have had a wound contaminated with Pu/Am in his left hand 16 yr previously. The wound had contained approx. 0.02-0.03 mu Ci 241Am initially, most of which was excised from the wound site after 50 days. Prompted by this knowledge we used a 50mm-diameter intrinsic Ge detector to examine the wound and relevant lymph node sites. The results demonstrated a localised deposit of 241Am in the axillary lymph nodes with approx. 1 nCi 241Am at the wound site. Subsequent measurements made with the phoswich detectors suggested that there was approx. 7 nCi 241Am in the lymph nodes with approx. 1 nCi 241Am in the liver, thereby accounting for most of the detectable 241Am contamination in the thorax.
Language of Publication
English
Unique Identifier
83237611

 


MeSH Heading (Major)
Americium|*AN; Germanium|*AN; Lymph Nodes|*AN; Radioisotopes|*AN
MeSH Heading
Axilla; Calibration; Case Report; Human; Male; Occupational Diseases|DI; Radiation Injuries|DI; Time Factors

Publication Type
JOURNAL ARTICLE
ISSN
0017-9078
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Radioisotopes); 7440-35-9 (Americium); 7440-56-4 (Germanium)

Record 27 from database: MEDLINE
Return To Menu Choice #20  

Title
Performance of an array of large-volume germanium detectors for whole-body counting.
Author
Palmer HE; Rieksts GA; Lynch TP
Address
Pacific Northwest Laboratory, Richland, WA 99352.
Source
Health Phys, 1991 Nov, 61:5, 595-600
Abstract
An array of four large-volume coaxial germanium detectors was installed in a shielded room for the in vivo measurement of gamma emitters in the body. All four detectors are in a single 50-L dewar of liquid nitrogen and are positioned underneath the supine subject with the axes of the detector elements parallel with the length of the body. This orientation gives approximately 15% more counting efficiency than having the axes of the detectors perpendicular to the body length. The detectors have resolutions that are less than 2 keV with an average of 1.86 keV for the 60Co 1.33-MeV gamma-ray peak. The efficiencies of the four detectors range from 59% to 77% of a 7.62- x 7.62-cm (3- x 3-in.) NaI (Tl) detector. The detectors are interfaced to a multichannel analyzer such that spectra from the detectors are stored both as a sum of all counts from the four detectors and as a spectrum from each detector. The sensitivity of the germanium array for measuring radioactivity in the body exceeds that of multiple large NaI (Tl) detectors for measuring single radionuclides in the body and is much superior for measuring internal depositions of radionuclide mixtures. Another major advantage of this system compared to NaI(Tl) systems is that the results can be calculated by computer analysis with minimal human interpretation. The sensitivity of the array configuration is described and applications of the array in other configurations, such as that used for measuring the very small quantities of 24Na induced in the body during air travel, are also discussed.
Language of Publication
English
Unique Identifier
92091145

 


MeSH Heading (Major)
Germanium|*; Whole-Body Counting|*IS
MeSH Heading
Bismuth|AN; Comparative Study; Human; Lead|AN; Polonium|AN; Radioisotopes|AN; Scintillation Counting; Support, U.S. Gov't, Non-P.H.S.

Publication Type
JOURNAL ARTICLE
ISSN
0017-9078
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Radioisotopes); 0 (Radon Daughters); 7439-92-1 (Lead); 7440-08-6 (Polonium); 7440-56-4 (Germanium); 7440-69-9 (Bismuth)

Record 28 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Germanium poisoning: clinical symptoms and renal damage caused by long-term intake of germanium.
Author
Obara K; Saito T; Sato H; Yamakage K; Watanabe T; Kakizawa M; Tsukamoto T; Kobayashi K; Hongo M; Yoshinaga K
Address
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Source
Jpn J Med, 1991 Jan-Feb, 30:1, 67-72
Abstract
We report five patients who have taken inorganic germanium preparations over a prolonged period. In all cases, the renal function deteriorated with no proteinuria or hematuria. Histological examination of the kidneys showed widespread tubular degeneration and interstitial fibrosis with minor glomerular abnormalities. Most patients had gastrointestinal symptoms such as vomiting, anorexia and weight loss; one patient had peripheral neuropathy and myopathy. A considerable amount of germanium was detected in the hair or nails of these patients. These cases clearly show that abuse of inorganic germanium compounds can induce renal damage with various extrarenal manifestations.
Language of Publication
English
Unique Identifier
91325443

 


MeSH Heading (Major)
Drugs, Non-Prescription|*PO; Gastrointestinal Diseases|*CI; Germanium|AD/AN/*PO; Kidney Diseases|*CI; Peripheral Nervous System Diseases|*CI
MeSH Heading
Aged; Anemia|CI; Case Report; Child; Fatigue|CI; Female; Hair|CH; Human; Male; Mental Retardation|DT; Middle Age; Nails|CH; Support, Non-U.S. Gov't

Publication Type
JOURNAL ARTICLE
ISSN
0021-5120
Country of Publication
JAPAN
CAS Registry/EC Number
0 (Drugs, Non-Prescription); 7440-56-4 (Germanium)

Record 29 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Nephrotoxicity in humans by the ultratrace element germanium.
Author
Schauss AG
Address
Life Sciences Division, American Institute for Biosocial Research, Inc., Tacoma, Washington 98401.
Source
Ren Fail, 1991, 13:1, 1-4
Abstract
Acute renal failure (ARF) or renal dysfunction (RD) associated with germanium-induced nephrotoxicity has been reported in 18 patients since 1982. In 2 of these cases the patients died of acute renal and cardiogenic failure. In 17 of 18 cases biopsies showed vacuolar degeneration in renal tubular epithelial cells in the absence of glomerular changes, without proteinuria or hematuria. Accumulated elemental Ge intake in 17 patients over a period of 4 to 36 months ranged between 16 and 328 g, or more than 100 to 2000 times the average estimated dietary intake of Ge for man (1.5 mg/d; range 0.40 to 3.40 mg/d). The biological half-life of Ge is 4.5 days for kidneys, the highest retention level of any organ. The mean concentration of Ge in healthy adult kidneys is 9.0 mg/kg wet weight. In 3 patients studied with Ge-induced RD or ARF, urinary Ge excretion was 9, 15, and 60 ng/mL, compared to greater than 5 ng/mL in healthy controls, and remained elevated even 12 months after discontinuing supplemental Ge intake. The mechanism for Ge-induced nephrotoxicity remains unknown, although the suspected cause is the inorganic Ge salts, such as germanium dioxide. Sufficient evidence for a role of organogermanium compounds, such as carboxyethyl germanium sesquioxide or citrate-lactate germanate, in Ge-induced nephrotoxicity remains lacking. The recent introduction of over-the-counter Ge "nutritional" supplements in some countries increases the risk of additional cases of Ge-induced nephrotoxicity, especially if appreciable levels of inorganic Ge salts are present and consumed for long periods (greater than 3 months) at levels above the average daily estimated dietary intake for Ge.(ABSTRACT TRUNCATED AT 250 WORDS)
Language of Publication
English
Unique Identifier
92021635

 


MeSH Heading (Major)
Germanium|AD/*AE/ME; Kidney Failure, Acute|*CI
MeSH Heading
Animal; Diet; Dose-Response Relationship, Drug; Half-Life; Human; Kidney|ME

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0886-022X
Country of Publication
UNITED STATES
CAS Registry/EC Number
7440-56-4 (Germanium)

Record 30 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Cytotoxic effects and biological activity of 2-aza-8-germanspiro[4,5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium) in vitro.
Author
Hill BT; Whatley SA; Bellamy AS; Jenkins LY; Whelan RD
Address
 
Source
Cancer Res, 1982 Jul, 42:7, 2852-6
Abstract
Lethal and other biological effects of 2-aza-8-germanspiro[4,5]decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium), representing a new chemical class of compound exhibiting antitumor activity, have been studied in vitro. Survival curves for NIL 8 hamster cells were exponential with greater kill occurring with increasing drug concentrations and longer exposure times. Cytotoxicity was temperature dependent. "Quiescent" cultures were significantly less sensitive to spirogermanium than were logarithmically growing cells. These lethal effects showed no phase specificity. There was no evidence of progression delay through the cycle following spirogermanium treatment. When spirogermanium was tested against a range of human cell lines, the consistency of the values for the drug concentration required to reduce survival by 50% on the exponential part of the survival curve, derived from colony-forming assays, was most marked. The survival curves, characterized by an initial shoulder, were steep and exponential with measurements possible over only a narrow concentration range since complete cell lysis occurred at levels causing a greater than 2-log kill. Cell membrane damage by spirogermanium, as judged by dye exclusion, was progressive with time and increasing drug concentrations. Protein synthesis proved most susceptible to the drug. Spirogermanium concentrations cytotoxic to tumor cells were also toxic to cultured rat neurons, confirming the clinical neurological toxicity encountered. The precise mode of action of spirogermanium remains to be established, and these data further illustrate its apparent lack of specificity.
Language of Publication
English
Unique Identifier
82208265

 


MeSH Heading (Major)
Antineoplastic Agents|*PD; Germanium|*PD; Spiro Compounds|*PD
MeSH Heading
Animal; Carcinoma, Squamous Cell|PA; Cell Cycle|DE; Cell Line; Cell Survival|DE; Cells, Cultured; Colonic Neoplasms|PA; Female; Hamsters; Human; Mesocricetus; Neuroblastoma|PA; Neurons|DE; Ovary|DE; Rats

Publication Type
JOURNAL ARTICLE
ISSN
0008-5472
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4 (Germanium)

Record 31 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  
 

Title
Determination of germanium and some other elements in hair, nail, and toenail from persons exposed and unexposed to germanium.
Author
Morita H; Shimomura S; Okagawa K; Saito S; Sakigawa C; Sato H
Address
 
Source
Sci Total Environ, 1986 Dec 31, 58:3, 237-42
Abstract
Inductively coupled atomic emission spectrometry was used for the determination of germanium in hair, nail, and toenail. The levels of germanium in three individuals administered a high concentration of a germanium preparation daily for about 12-16 months were very high: 56.4-173.7; 5.4-35.0; and 14.0-15.8 micrograms g-1 in hair, nail, and toenail, respectively. The levels for normal or unexposed persons are very low and were not detected by the method.
Language of Publication
English
Unique Identifier
87148999

 


MeSH Heading (Major)
Environmental Exposure|*; Germanium|*AN; Hair|*AN; Nails|*AN
MeSH Heading
Adult; Comparative Study; Female; Foot; Hand; Human; Kidney Diseases|ME; Male; Muscular Diseases|ME; Reference Values; Spectrum Analysis

Publication Type
JOURNAL ARTICLE
ISSN
0048-9697
Country of Publication
NETHERLANDS
CAS Registry/EC Number
7440-56-4 (Germanium)

Record 32 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Rotating laminar emission camera with GE-detector: an analysis.
Author
Mauderli W; Fitzgerald LT; Urie MM; Tosswill H
Address
 
Source
Med Phys, 1981 Nov-Dec, 8:6, 871-6
Abstract
Design criteria for a germanium detector emission camera with laminar collimator-detector geometry are reported. In this design, parallel plates above a grooved germanium slab form detector channels which accumulate data in multiple projections through 180 degrees. Activity distribution is determined through mathematical reconstruction from the projections. The laminar design has greater efficiency than a hole-collimated device due to a favorable open area ratio and due to collimation in only one dimension. The relative sensitivity at the center of the detector strip increases with detector length and distance from collimator face. Spatial resolution depends upon the design geometry (septal penetration and scatter within the crystal are of such small magnitude that degradation of the point spread function is minimal). A 30 channel protype device (ROLEC) shows good correlation with theoretically determined PSF and signal-to-noise ratio (SNR). Measuring times projected for a clinical sized device (300 mm diam) are about 4.6 times that of the Anger camera (with same SNR) and high resolution collimator.
Language of Publication
English
Unique Identifier
82103582

 


MeSH Heading (Major)
Germanium|*; Radionuclide Imaging|*IS
MeSH Heading
Human

Publication Type
JOURNAL ARTICLE
ISSN
0094-2405
Country of Publication
UNITED STATES
CAS Registry/EC Number
7440-56-4 (Germanium)

Record 33 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
 

Title
Rotating laminar emission camera with GE-detector: experimental results.
Author
Urie MM; Mauderli W; Fitzgerald LT; Williams CM; Tosswill CH
Address
 
Source
Med Phys, 1981 Nov-Dec, 8:6, 865-70
Abstract
Experimental results of a prototype rotating laminar emission camera (ROLEC) for nuclear medicine imaging are reported. A 11.5 mm thick, 45 x 45 mm high-purity germanium detector is segmented into 30 1.47 mm wide parallel channels and collimated with 39 mm high parallel plates. Projection data acquired at multiple angular orientations as the detector-collimator assembly is rotated about its center are mathematically reconstructed to image the activity distribution. The spatial resolution of the ROLEC is at least twice as good, at all distances, as that of gamma cameras with high resolution collimators. The better energy resolution of the germanium enhances the detection and resolution of the ROLEC in comparison to gamma cameras with NaI(T1) crystals, the relative superiority increasing with greater volumes and with greater depths. Adequate sensitivity is maintained while achieving these improvements in spatial resolution and in practice; ROLEC images are acquired in less time than pinhole collimator images with gamma cameras.
Language of Publication
English
Unique Identifier
82103581

 


MeSH Heading (Major)
Germanium|*; Radionuclide Imaging|*IS
MeSH Heading
Animal; Human; Rats

Publication Type
JOURNAL ARTICLE
ISSN
0094-2405
Country of Publication
UNITED STATES
CAS Registry/EC Number
7440-56-4 (Germanium)

Record 34 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Cerebral distribution of 133-Xe and blood flow measured with high purity germanium.
Author
Reich T; Rusinek H; Youdin M; Clagnaz M
Address
 
Source
Stroke, 1985 Jan-Feb, 16:1, 92-101
Abstract
Distribution of cerebral blood flow was measured with an array of 200 ultra-pure germanium radiation detectors and 133-Xe by inhalation. The array "sees" the head as a composite of different subvolumes and enables measurement of the concentration history of tracer every 1-10 sec in each subvolume simultaneously. Subvolume mean flows, (fm), and partition coefficients, lambda m, are derived by compartmental analysis of tissue concentration washout curves. Errors from "cross talk," scalp radiation, "look through," and assumed partition coefficients are eliminated. Average fm adjusted for 40 mm Hg PACO2 in 14 cortical subvolumes (7 right, 7 left) of four normal 21-24 year old controls ranged from 50 to 60 ml/100 cc tissue/min, and lambda m ranged from 0.97 to 1.14. Average fm and lambda m in white matter was 24 ml/100 cc/min and 1.42 - 1.14 respectively. During CO2 inhalation, right and left hemispheric fm increased 6.4% and 5.7%/mm Hg respectively, whereas white matter fm increased 2.2% and 3.4% mm Hg respectively. There was no systematic difference between front and back or dominant vs non-dominant sides. Three 73-84 year old controls had reduced fm and CO2 reactivity in all subvolumes, lambda m was in the same range as in younger controls. Two patients with intracranial cerebrovascular disease showed excellent localization of ischemic subvolumes. One patient with asymptomatic unilateral 98% stenosis of the internal carotid artery had a similar distribution of blood flow in both hemispheres.
Language of Publication
English
Unique Identifier
85091359

 


MeSH Heading (Major)
Cerebrovascular Circulation|*; Cerebrovascular Disorders|*PP/RI; Germanium|*DU; Xenon Radioisotopes|*DU
MeSH Heading
Adult; Aged; Carbon Dioxide; Female; Human; Male; Partial Pressure; Support, Non-U.S. Gov't; Tomography, Emission-Computed|IS/MT

Publication Type
JOURNAL ARTICLE
ISSN
0039-2499
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Xenon Radioisotopes); 124-38-9 (Carbon Dioxide); 7440-56-4 (Germanium)

Record 35 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
A phase II study of spirogermanium in advanced human malignancy.
Author
Vogelzang NJ; Gesme DH; Kennedy BJ
Address
 
Source
Am J Clin Oncol, 1985 Aug, 8:4, 341-4
Abstract
Spirogermanium, a heavy metal compound in which germanium has been substituted in an azaspirane ring structure, was studied in 39 patients with advanced malignant neoplasms. Thirty-one patients were considered evaluable for toxic effects of spirogermanium. Transient neurological symptoms occurred in 12 patients (39%), including dizziness or lightheadedness, marked fatigue, visual blurring, ataxia, paresthesia, and nausea. These symptoms could be reduced by infusing the drug over 2 hours rather than over 1 hour. Persistent neurotoxicity in the form of partial loss of taste or extreme weakness was observed in three patients. No evidence of hematologic, renal, or hepatic toxicity was observed. Antitumor activity of spirogermanium was not identified in this group of heavily pretreated patients. Spirogermanium had limited and acceptable toxicity in utilizing a dose of 120 mg/m2 infused over 2 hours, three times weekly.
Language of Publication
English
Unique Identifier
86100364

 


MeSH Heading (Major)
Germanium|AD/AE/*TU; Neoplasms|*DT; Spiro Compounds|AD/AE/*TU
MeSH Heading
Adult; Aged; Clinical Trials; Drug Administration Schedule; Drug Evaluation; Female; Half-Life; Human; Infusions, Parenteral; Kinetics; Male; Middle Age

Publication Type
CLINICAL TRIAL; JOURNAL ARTICLE
ISSN
0277-3732
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4 (Germanium)

Record 36 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Accumulation of germanium in the tissues of a long-term user of germanium preparation died of acute renal failure.
Author
Nagata N; Yoneyama T; Yanagida K; Ushio K; Yanagihara S; Matsubara O; Eishi Y
Address
 
Source
J Toxicol Sci, 1985 Nov, 10:4, 333-41
Abstract
Acute renal failure developed in a patient accompanied by systemic manifestations such as myopathy and skin rash. The patient, a middle aged house wife, had been taking 600 mg of germanium (Ge) preparation daily for 18 months as an elixir. The main component of the preparation was GeO2 and some organic compound was also present. Histological study of the kidney post mortem showed foamy cell transformation of glomerular epithelia, degeneration of tubular epithelia with red blood cell casts and urate crystals, and a mild proliferation of mesangial matrix. Analysis of the tissue content of Ge, prompted by her history, revealed an increased accumulation of the metal. As compared to a non-user died of liver cirrhosis, the concentration of the metal was higher particularly in the spleen (183X), thyroid gland (175X), psoas muscle (93X), jejunum (76X), and renal cortex (69X). So far, neither accumulation of Ge in humal tissue nor systemic toxicity of the Ge in human has been reported. The relevance of massive accumulation of Ge to the renal failure as well as to other systemic manifestations the patient presented remains to be clarified.
Language of Publication
English
Unique Identifier
86171879

 


MeSH Heading (Major)
Germanium|AD/AE/*ME; Kidney Failure, Acute|*CI/PA
MeSH Heading
Case Report; Female; Human; Kidney|PA; Tissue Distribution

Publication Type
JOURNAL ARTICLE
ISSN
0388-1350
Country of Publication
JAPAN
CAS Registry/EC Number
7440-56-4 (Germanium)

Record 37 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20
 

Title
A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study.
Author
Eisenhauer E; Quirt I; Connors JM; Maroun J; Skillings J
Address
 
Source
Invest New Drugs, 1985, 3:3, 307-10
Abstract
The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of spirogermanium given daily for 5 days every 3 weeks to patients with poor prognosis non-Hodgkin's lymphomas. All patients had had a maximum of one prior treatment regimen. No responses were seen in 13 evaluable patients. Toxicity was primarily neurologic and mild or moderate in most patients. There is no evidence of activity of spirogermanium given in this schedule in this subset of lymphoma patients.
Language of Publication
English
Unique Identifier
86058482

 


MeSH Heading (Major)
Antineoplastic Agents|AE/*TU; Germanium|AE/*TU; Lymphoma|*DT; Spiro Compounds|AE/*TU
MeSH Heading
Aged; Drug Evaluation; Human; Middle Age; Nervous System Diseases|CI; Prognosis

Publication Type
JOURNAL ARTICLE
ISSN
0167-6997
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4 (Germanium)

Record 38 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
A phase II study of spirogermanium in patients with metastatic malignant melanoma. An NCI Canada Clinical Trials Group Study.
Author
Eisenhauer E; Kerr I; Bodurtha A; Iscoe N; McCulloch P; Pritchard K; Quirt I
Address
 
Source
Invest New Drugs, 1985, 3:3, 303-5
Abstract
The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of spirogermanium given daily for 5 days every 3 weeks to previously untreated patients with malignant melanoma. In 21 evaluable patients one complete response was seen (response rate 5%). Disease progression occurred in the other 20 patients. Toxicity was primarily neurologic and mild or moderate in most patients, though there was one treatment related death. In this schedule spirogermanium has extremely limited activity against malignant melanoma and will not contribute significantly to the systemic therapy of this disease.
Language of Publication
English
Unique Identifier
86058481

 


MeSH Heading (Major)
Antineoplastic Agents|AE/*TU; Germanium|AE/*TU; Melanoma|*DT/PA; Spiro Compounds|AE/*TU
MeSH Heading
Adult; Aged; Drug Evaluation; Female; Human; Male; Middle Age; Neoplasm Metastasis

Publication Type
JOURNAL ARTICLE
ISSN
0167-6997
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Antineoplastic Agents); 0 (Spiro Compounds); 41992-23-8 (spirogermanium); 7440-56-4 (Germanium)

Record 39 from database: MEDLINE
Return To Top Of Menu
Return To Menu Choice #20  

Title
Germanium dioxide-induced nephropathy: a new type of renal disease.
Author
Sanai T; Okuda S; Onoyama K; Oochi N; Oh Y; Kobayashi K; Shimamatsu K; Fujimi S; Fujishima M
Address
Second Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Source
Nephron, 1990, 54:1, 53-60
Abstract
Chronic renal failure developed in 5 patients who were taking germanium dioxide (GeO2)-containing compounds. Renal functional deterioration was slow but progressive and dialysis treatment was necessitated temporarily in 2 patients. After the discontinuation of GeO2, the impaired renal function tended to improve but remained abnormal for an observation period of 10-40 months. The lack of proteinuria and hematuria was characterized as the clinical manifestations. Renal biopsy specimens revealed the tubular epithelial cell degeneration containing hematoxylin-positive fine granules on light microscopy, and electron-dense inclusions in the swollen mitochondria on electron microscopy. These findings localized mainly in distal segment of the tubules. In the rats given GeO2 orally for 10 weeks, similar histological lesions were evident, as manifested by marked weight loss, anemia, azotemia, and negative proteinuria. In the rats given carboxyethylgermanium sesquioxide, these changes were not observed and Ge concentration of kidney was significantly lower than in the rats given GeO2. The present study indicates that chronic GeO2 intake causes progressive renal dysfunction characterized by the degeneration of distal tubules.
Language of Publication
English
Unique Identifier
90114564

 


MeSH Heading (Major)
Germanium|*AE/TO; Kidney Failure, Chronic|*CI/PA
MeSH Heading
Adolescence; Adult; Animal; Case Report; Female; Human; Male; Middle Age; Rats; Rats, Inbred Strains; Support, Non-U.S. Gov't

Publication Type
JOURNAL ARTICLE
ISSN
0028-2766
Country of Publication
SWITZERLAND
CAS Registry/EC Number
1310-53-8 (germanium oxide); 7440-56-4 (Germanium)

Special Pages On The Various of Web Sites Authored by Karl Loren
OC History Oral Chelation Testimonials
Family Of Three Oral Chelation Formulas Life Glow Basic Life Glow Basic Ingredient List
Life Glow Plus Life Glow Plus
Ingredient List
American Heart Association -- Lies
Super Life Glow Super Life Glow
 Ingredient List
FAQ